NCT06384976Not yet recruitingPhase 2
A Study of Anti-CD19 CAR T-cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis
A Phase 2, Open-Label, Randomized, Multicenter Study of KYV101, an Autologous Fully Human Anti-CD19 Chimeric Antigen Receptor T Cell (CD19 CAR T) Therapy, in Subjects with Refractory Primary and Secondary Progressive Multiple Sclerosis (KYSA-7)
Source: EU CTIS (euclinicaltrials.eu) · Last updated 31 Aug 2026
Brief summary (registry, in English)
1. To evaluate the efficacy of KYV-101
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 88 (estimated)
- First submitted
- 24 May 2024
- Start date
- 23 Apr 2027
- Lead sponsor
- Kyverna Therapeutics Inc.
- Diseases
- Multiple sclerosis
- NCT number
- NCT06384976
- EU CT number
- 2024-511168-10-00
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 88
- 10 sites in 4 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.
Who cannot take part
Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.
Other illness
- Monophasic disease, radiologically isolated syndrome, clinically isolated syndrome, progressive solitary sclerosis or relapsing-remitting disease as defined by the 2017 McDonald criteria (Thompson 2018).
- History of neuromyelitis optica spectrum disorder (NMOSD) or myelin oligodendrocyte glycoprotein (MOG) antibody associated disease (MOGAD).
Who the study is looking for
- Subject must be 18 to 60 years of age (inclusive).
- Subject must have a history of diagnosis of PPMS or SPMS
- History of treatment with anti-CD20 mAb with continuing evidence of worsening physical disability over a period of ≥6 months with documented evidence of clinical disability progression within the 2 years prior to inclusion. Patients with active SPMS should also have shown inadequate response or intolerance to another DMT (e.g., sphingosine-1-phosphate (S1P) receptor modulator), subject to availability.
Age in the registry: 18 years to 64 years · Sex: All · Does not accept healthy volunteers
Sites (10)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Medical University of Vienna Coordinator of this site? Confirm its status | Vienna | Austria | Not yet recruiting |
| Antwerp University Hospital Coordinator of this site? Confirm its status | Edegem | Belgium | Not yet recruiting |
| Charite Universitaetsmedizin Berlin KöR Coordinator of this site? Confirm its status | Berlin | Germany | Not yet recruiting |
| Katholisches Klinikum Bochum gGmbH Coordinator of this site? Confirm its status | Bochum | Germany | Not yet recruiting |
| Universitaetsklinikum Carl Gustav Carus Dresden an der Technischen Universitaet Dresden AöR Coordinator of this site? Confirm its status | Dresden | Germany | Not yet recruiting |
| University Medical Center Hamburg-Eppendorf Coordinator of this site? Confirm its status | Hamburg | Germany | Not yet recruiting |
| Medizinische Hochschule Hannover Coordinator of this site? Confirm its status | Hanover | Germany | Not yet recruiting |
| Universitaetsklinikum Jena KöR Coordinator of this site? Confirm its status | Jena | Germany | Not yet recruiting |
| Klinikum rechts der Isar der TU Muenchen AöR Coordinator of this site? Confirm its status | Munich | Germany | Not yet recruiting |
| Ospedale San Raffaele S.r.l. Coordinator of this site? Confirm its status | Milan | Italy | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.